BrightAccountsProduction v1.0.0 v1.0.0 2024-04-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts The principal activity of the company is the preparation and retail of pharmaceutical and medicinal products. 28 August 2025 9 9 NI028001 2025-03-31 NI028001 2024-03-31 NI028001 2023-03-31 NI028001 2024-04-01 2025-03-31 NI028001 2023-04-01 2024-03-31 NI028001 uk-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 NI028001 uk-curr:PoundSterling 2024-04-01 2025-03-31 NI028001 uk-bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 NI028001 uk-bus:FullAccounts 2024-04-01 2025-03-31 NI028001 uk-bus:Director1 2024-04-01 2025-03-31 NI028001 uk-bus:RegisteredOffice 2024-04-01 2025-03-31 NI028001 uk-bus:Agent1 2024-04-01 2025-03-31 NI028001 uk-core:ShareCapital 2025-03-31 NI028001 uk-core:ShareCapital 2024-03-31 NI028001 uk-core:RetainedEarningsAccumulatedLosses 2025-03-31 NI028001 uk-core:RetainedEarningsAccumulatedLosses 2024-03-31 NI028001 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2025-03-31 NI028001 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-03-31 NI028001 uk-bus:FRS102 2024-04-01 2025-03-31 NI028001 uk-core:LandBuildings 2024-04-01 2025-03-31 NI028001 uk-core:PlantMachinery 2024-04-01 2025-03-31 NI028001 uk-core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 NI028001 uk-core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 NI028001 uk-core:CurrentFinancialInstruments 2025-03-31 NI028001 uk-core:CurrentFinancialInstruments 2024-03-31 NI028001 uk-core:WithinOneYear 2025-03-31 NI028001 uk-core:WithinOneYear 2024-03-31 NI028001 uk-core:EmployeeBenefits 2024-03-31 NI028001 uk-core:EmployeeBenefits 2024-04-01 2025-03-31 NI028001 uk-core:AcceleratedTaxDepreciationDeferredTax 2025-03-31 NI028001 uk-core:TaxLossesCarry-forwardsDeferredTax 2025-03-31 NI028001 uk-core:OtherDeferredTax 2025-03-31 NI028001 uk-core:RevaluationPropertyPlantEquipmentDeferredTax 2025-03-31 NI028001 uk-core:EmployeeBenefits 2025-03-31 NI028001 uk-core:ParentEntities 2024-04-01 2025-03-31 NI028001 2024-04-01 2025-03-31 NI028001 uk-bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 xbrli:pure iso4217:GBP xbrli:shares

Company Registration Number: NI028001

Newpharm Ltd

Unaudited Financial Statements

for the financial year ended 31 March 2025

Newpharm Ltd

DIRECTOR AND OTHER INFORMATION

Director | Mr. Richard Garvey
Company Registration Number | NI028001
Registered Office | 42 Dernaroy Road
| Killeavy
| Newry
| Co. Down
| BT35 8SP
| Northern Ireland
Business Address | Newry Health Village
| Monaghan Street
| Newry
| Co. Down
| BT35 6BW
| United Kingdom
Accountants | MG accountants
| (Portadown)
| 25-27 Carleton Street
| Portadown
| Co. Armagh
| BT62 3EP
Bankers | Danske Bank
| 58 Hill Street
| Newry
| Co. Armagh
| BT34 1AR
| United Kingdom

Newpharm Ltd

Company Registration Number: NI028001

BALANCE SHEET

as at 31 March 2025

|  |  | 2025 |  | 2024
|  | Notes | £ |  | £
Fixed Assets

Tangible assets |  | 4 | 43,758 |  | 44,693
|  |  | ───────── |  | ─────────
Current Assets

Stocks |  | 5 | 95,000 |  | 95,000
Debtors |  | 6 | 377,914 |  | 250,071
Cash and cash equivalents |  |  | 56,025 |  | 77,580
|  |  | ───────── |  | ─────────
|  |  | 528,939 |  | 422,651
|  |  | ───────── |  | ─────────
Creditors: amounts falling due within one year |  | 7 | (224,986) |  | (198,293)
|  |  | ───────── |  | ─────────
Net Current Assets |  |  | 303,953 |  | 224,358
|  |  | ───────── |  | ─────────
Total Assets less Current Liabilities |  |  | 347,711 |  | 269,051
Provisions for liabilities |  | 9 | (3,439) |  | (3,673)
|  |  | ───────── |  | ─────────
Net Assets |  |  | 344,272 |  | 265,378
|  |  | ═════════ |  | ═════════
Capital and Reserves

Called up share capital |  |  | 8 |  | 8
Retained earnings |  |  | 344,264 |  | 265,370
|  |  | ───────── |  | ─────────
Equity attributable to owners of the company |  |  | 344,272 |  | 265,378
|  |  | ═════════ |  | ═════════
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).

The company has taken advantage of the exemption under section 444 not to file the Profit and Loss Account and Director's Report.

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Approved by the Director and authorised for issue on 28 August 2025

________________________________ |  |  |  |  |
Mr. Richard Garvey |  |  |  |  |
Director |  |  |  |  |

Newpharm Ltd

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

1. | General Information
| Newpharm Ltd is a company limited by shares incorporated and registered in Northern Ireland. The registered number of the company is NI028001. The registered office of the company is 42 Dernaroy Road, Killeavy, Newry, Co. Down, BT35 8SP, Northern Ireland. The principal activity of the company is the preparation and retail of pharmaceutical and medicinal products. The financial statements have been presented in Pound (£) which is also the functional currency of the company.

2. | Summary of Significant Accounting Policies
| The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
| Statement of compliance
| The financial statements of the company for the financial year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
| Basis of preparation
| The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
| Turnover
| Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
| Tangible assets and depreciation
| Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
|  | Land and buildings freehold | - | 4% Straight line
|  | Equipment | - | 15% Straight line
|  | Fixtures & fittings | - | 15% Straight line
|  | Licence | - |
| The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
| Stocks
| Stocks are valued at the lower of cost and net realisable value.
| Trade and other debtors
| Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
| Provisions
| Provisions are recognised when the company has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the same value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.
| Trade and other creditors
| Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
| Taxation and deferred taxation
| Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date. Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
| Ordinary share capital
| The ordinary share capital of the company is presented as equity.

3. | Employees
| The average monthly number of employees, including director, during the financial year was 9, (2024 - 9).
|  | 2025 | 2024
|  | Number | Number
| Shop Staff | 9 | 9
|  | ═════════ | ═════════

4. | Tangible assets
|  | Land and | Equipment | Fixtures | Licence | Total
|  | buildings |  | & fittings |  |
|  | freehold |  |  |  |
|  | £ | £ | £ | £ | £
| Cost
| At 1 April 2024 | 31,253 | 20,138 | 95,827 | 30,000 | 177,218
| Additions | - | - | 2,505 | - | 2,505
|  | ───────── | ───────── | ───────── | ───────── | ─────────
| At 31 March 2025 | 31,253 | 20,138 | 98,332 | 30,000 | 179,723
|  | ───────── | ───────── | ───────── | ───────── | ─────────
| Depreciation
| At 1 April 2024 | 31,253 | 16,926 | 84,346 | - | 132,525
| Charge for the financial year | - | 643 | 2,797 | - | 3,440
|  | ───────── | ───────── | ───────── | ───────── | ─────────
| At 31 March 2025 | 31,253 | 17,569 | 87,143 | - | 135,965
|  | ───────── | ───────── | ───────── | ───────── | ─────────
| Net book value
| At 31 March 2025 | - | 2,569 | 11,189 | 30,000 | 43,758
|  | ═════════ | ═════════ | ═════════ | ═════════ | ═════════
| At 31 March 2024 | - | 3,212 | 11,481 | 30,000 | 44,693
|  | ═════════ | ═════════ | ═════════ | ═════════ | ═════════

5. | Stocks | 2025 | 2024
|  | £ | £
| Finished goods and goods for resale | 95,000 | 95,000
|  | ═════════ | ═════════
| The replacement cost of stock did not differ significantly from the figures shown.

6. | Debtors | 2025 | 2024
|  | £ | £
| Trade debtors | 108,272 | 97,634
| Amounts owed by related parties | 249,094 | 135,161
| Taxation (Note 8) | 17,117 | 17,276
| Prepayments and accrued income | 3,431 | -
|  | ───────── | ─────────
|  | 377,914 | 250,071
|  | ═════════ | ═════════

7. | Creditors | 2025 | 2024
| Amounts falling due within one year | £ | £
| Trade creditors | 191,312 | 190,505
| Taxation (Note 8) | 29,989 | 5,353
| Accruals | 3,685 | 2,435
|  | ───────── | ─────────
|  | 224,986 | 198,293
|  | ═════════ | ═════════

8. | Taxation | 2025 | 2024
|  | £ | £
| Debtors:
| VAT | 17,117 | 17,276
|  | ═════════ | ═════════
| Creditors:
| Corporation tax | 26,532 | 1,435
| PAYE / NI | 3,457 | 3,918
|  | ───────── | ─────────
|  | 29,989 | 5,353
|  | ═════════ | ═════════

9. | Provisions for liabilities
| The amounts provided for deferred taxation are analysed below:
|  | Capital | Total | Total
|  | allowances |  |
|  |  | 2025 | 2024
|  | £ | £ | £
| At financial year start | 3,673 | 3,673 | 1,966
| Charged to profit and loss | (234) | (234) | 1,707
|  | ───────── | ───────── | ─────────
| At financial year end | 3,439 | 3,439 | 3,673
|  | ═════════ | ═════════ | ═════════

10. | Capital commitments
| The company had no material capital commitments at the financial year-ended 31 March 2025.

11. | Parent company
| The company regards Meigh Pharmacy Limited as its parent company.

12. | Post-Balance Sheet Events
| There have been no significant events affecting the company since the financial year-end.